C4 Therapeutics (CCCC) Retained Earnings: 2019-2025
Historic Retained Earnings for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to -$718.2 million.
- C4 Therapeutics' Retained Earnings fell 19.88% to -$718.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$718.2 million, marking a year-over-year decrease of 19.88%. This contributed to the annual value of -$633.7 million for FY2024, which is 19.93% down from last year.
- According to the latest figures from Q3 2025, C4 Therapeutics' Retained Earnings is -$718.2 million, which was down 4.69% from -$686.0 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Retained Earnings registered a high of -$204.8 million during Q1 2021, and its lowest value of -$718.2 million during Q3 2025.
- Moreover, its 3-year median value for Retained Earnings was -$574.5 million (2024), whereas its average is -$577.1 million.
- Data for C4 Therapeutics' Retained Earnings shows a maximum YoY tumbled of 55.59% (in 2021) over the last 5 years.
- C4 Therapeutics' Retained Earnings (Quarterly) stood at -$267.7 million in 2021, then plummeted by 47.88% to -$395.9 million in 2022, then plummeted by 33.47% to -$528.4 million in 2023, then dropped by 19.93% to -$633.7 million in 2024, then dropped by 19.88% to -$718.2 million in 2025.
- Its Retained Earnings was -$718.2 million in Q3 2025, compared to -$686.0 million in Q2 2025 and -$660.0 million in Q1 2025.